Category Press Releases

WuXi AppTec’s Nantong Facility Honored with 2025 Architizer A+Award for Seamlessly Integrating Technology and Human-Centered Design

WuXi AppTec’s Nantong Facility Wins 2025 Architizer A+Award for Excellence in Human-Centered Industrial Design WuXi AppTec, a globally recognized provider of research, development, and manufacturing services for the pharmaceutical and life sciences industries, has proudly announced that its Nantong facility…

Read MoreWuXi AppTec’s Nantong Facility Honored with 2025 Architizer A+Award for Seamlessly Integrating Technology and Human-Centered Design

U.S. FDA Grants Orphan Drug Designation to Riliprubart for Treating Antibody-Mediated Rejection in Solid Organ Transplant Recipients

Sanofi’s Riliprubart Receives U.S. FDA Orphan Drug Designation for Antibody-Mediated Rejection in Solid Organ Transplantation The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to riliprubart, an investigational immunology therapy developed by Sanofi, for the treatment…

Read MoreU.S. FDA Grants Orphan Drug Designation to Riliprubart for Treating Antibody-Mediated Rejection in Solid Organ Transplant Recipients

FDA Approves CSL’s Andembry First Once-Monthly Prophylactic HAE Treatment Targeting Factor XIIa

FDA Approves ANDEMBRY (garadacimab-gxii) The First Once-Monthly Prophylactic HAE Therapy Targeting Factor XIIa CSL a leading biotechnology company with a strong track record of developing innovative medicines for patients with rare and serious disorders, today announced that the U.S. Food…

Read MoreFDA Approves CSL’s Andembry First Once-Monthly Prophylactic HAE Treatment Targeting Factor XIIa

Dapirolizumab Pegol Phase 3 Data Shows Fatigue Improvement and Disease Activity Reduction at EULAR

Dapirolizumab Pegol Shows Disease Activity Reduction and Fatigue Improvement in SLE at EULAR 2025 UCB and Biogen today presented additional and detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel, Fc-free, anti-CD40 Ligand (anti-CD40L)…

Read MoreDapirolizumab Pegol Phase 3 Data Shows Fatigue Improvement and Disease Activity Reduction at EULAR

Rilzabrutinib Cuts Flares in IgG4-Related Disease; Fast Track Granted in US

EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers…

Read MoreRilzabrutinib Cuts Flares in IgG4-Related Disease; Fast Track Granted in US

Dapirolizumab Pegol Phase 3 Data Shows SLE Fatigue and Disease Activity Improvement at EULAR

Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive new findings from their Phase 3 PHOENYCS GO clinical trial…

Read MoreDapirolizumab Pegol Phase 3 Data Shows SLE Fatigue and Disease Activity Improvement at EULAR